XSTO
KLAR
Market cap6mUSD
Jun 09, Last price
0.41SEK
1D
-3.04%
1Q
-62.52%
Jan 2017
-94.75%
IPO
-90.99%
Name
Klaria Pharma Holding AB (publ)
Chart & Performance
Profile
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 2,248 | 5,868 -3.99% | ||||||||
Cost of revenue | 33,533 | 14,902 | 61,511 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (31,285) | (14,902) | (55,643) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 18 | (57) | 117 | |||||||
Tax Rate | ||||||||||
NOPAT | (31,303) | (14,845) | (55,760) | |||||||
Net income | (47,750) 33.44% | (35,784) -43.89% | (63,774) 19.13% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (18) | 16,371 | 41,734 | |||||||
BB yield | 0.04% | -35.15% | -61.92% | |||||||
Debt | ||||||||||
Debt current | 18,932 | 16,743 | ||||||||
Long-term debt | 1,359 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 619 | |||||||||
Net debt | (598) | 17,685 | 1,341 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (11,935) | (9,058) | (49,729) | |||||||
CAPEX | (42) | |||||||||
Cash from investing activities | (2) | (42) | ||||||||
Cash from financing activities | 11,272 | (6,457) | 41,056 | |||||||
FCF | 76,926 | (72,985) | (55,107) | |||||||
Balance | ||||||||||
Cash | 598 | 1,247 | 16,761 | |||||||
Long term investments | ||||||||||
Excess cash | 486 | 1,247 | 16,468 | |||||||
Stockholders' equity | (45,339) | (237,874) | (96,957) | |||||||
Invested Capital | 49,263 | 297,940 | 189,750 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 124,620 | 100,798 | 58,102 | |||||||
Price | 0.34 -27.49% | 0.46 -60.17% | 1.16 -81.20% | |||||||
Market cap | 41,748 -10.35% | 46,569 -30.91% | 67,398 -80.23% | |||||||
EV | 41,148 | 64,256 | 68,763 | |||||||
EBITDA | (20,066) | (14,893) | (44,609) | |||||||
EV/EBITDA | ||||||||||
Interest | 3,777 | 7,843 | ||||||||
Interest/NOPBT |